<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669006</url>
  </required_header>
  <id_info>
    <org_study_id>R-07-835</org_study_id>
    <secondary_id>13930E</secondary_id>
    <nct_id>NCT00669006</nct_id>
  </id_info>
  <brief_title>Neuropathic Pain Database</brief_title>
  <acronym>NePDatabase</acronym>
  <official_title>National Neuropathic Pain Database Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canada Foundation for Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the infrastructure for a national neuropathic pain database.&#xD;
&#xD;
      To determine the longterm outcome of the management of chronic neuropathic pain including&#xD;
      pain relief, disability, and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The database will provide standard information on demographics, diagnosis, treatment&#xD;
      interventions and outcome modeled on guidelines from the expert panel on initiatives on&#xD;
      Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT)(Turk et al.,Pain&#xD;
      2003;106:337-345) The IMMPACT panel determined that patients should be evaluated according to&#xD;
      six core domains as follows: Pain, physical functioning, emotional functioning, subject&#xD;
      rating of global satisfaction with treatment, symptoms and adverse events and subject&#xD;
      disposition.&#xD;
&#xD;
      The database will allow us to examine outcomes based on single (eg. pregabalin) and multiple&#xD;
      (e.g tricyclic antidepressants and gabalin) therapeutic interventions. Standard guidelines&#xD;
      for management of neuropathic pain acknowledge that polypharmacy is appropriate when&#xD;
      individual first line treatments fail to provide adequate pain relief (Gilron I et al., CMAJ&#xD;
      2006; 175: 265-275; Attal N et al., European Journal of Neurology 2006; 13: 1153-1169)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 24, 2020</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the infrastructure for a national Neuropathic Pain Database.</measure>
    <time_frame>2 years</time_frame>
    <description>To establish the infrastructure for a National Neuropathic Pain Database, with a composite primary outcome measure in average pain intensity (based on average pain intensity of BPI) and reduction in disability (based on Interference Scale Score of BPI))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the longterm outcome of the management of chronic neuropathic pain including pain relief, disability and quality of life.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">789</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>New patients with a diagnosis of Neuropathic Pain</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        New patients referred to the outpatient pain clinic with a diagnosis of Neuropathic Pain.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primarily Neuropathic Pain&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Estimated Life Expectancy of 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not primarily neuropathic pain&#xD;
&#xD;
          -  Declined participation- too much traveling&#xD;
&#xD;
          -  Declined participation- Unknown&#xD;
&#xD;
          -  Declined participation- Other, specify&#xD;
&#xD;
          -  Considered unreliable- personality disorder&#xD;
&#xD;
          -  Considered unreliable- cognitive impairment&#xD;
&#xD;
          -  Considered unreliable- substance abuse&#xD;
&#xD;
          -  Considered unreliable- Other&#xD;
&#xD;
          -  Language barrier&#xD;
&#xD;
          -  Exceeded quarterly quota&#xD;
&#xD;
          -  Presentation with progressive or recurrent cancer, fibromyalgia, perineal pain of&#xD;
             unknown etiology&#xD;
&#xD;
          -  Other, specify&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight Moulin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre- St. Joseph's Health Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre- St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropathic pain</keyword>
  <keyword>database</keyword>
  <keyword>prospective</keyword>
  <keyword>national</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

